Scientists might choose indirect delivery for gene therapy for several reasons, including:
-
Safety and Control: Indirect delivery often allows for better control over the therapeutic process. By modifying cells ex vivo (outside the body), scientists can ensure that the cells have been properly modified and are producing the correct protein before being introduced back into the patient.
-
Reducing Side Effects: Indirect delivery can minimize potential side effects and risks associated with the use of vectors (like viruses) that might provoke an immune response or lead to inappropriate targeting of genes in non-target tissues.
-
Targeted Application: When genetically modified cells are delivered through indirect methods, there is often an increased ability to target specific tissues or organs more effectively compared to direct delivery methods.
-
Cell Viability: It may be easier to monitor and ensure the viability of genetically modified cells in a laboratory setting before reintroducing them into the body, compared to the potential complications introduced during direct delivery.
-
Complexity of the Target Area: As stated in the option, direct gene delivery is not always possible if the target area is difficult to access. Indirect delivery can circumvent these limitations by preparing and manipulating cells in a controlled environment before they are administered to the patient.
In summary, the choice of indirect delivery is often based on the benefits of ensuring proper modification, safety, reduced side effects, and better targeting, especially when the target area is not easily accessible.